Name: Dr. Shira Zelber-Sagi Date: December...

1

Name: Dr. Shira Zelber-Sagi Date: December 2014

CURRICULUM VITAE

1. Personal Details

Name: Shira Zelber-Sagi

Date of Birth: March 9, 1974

Country of Birth: Israel

Identity Card Number: 02728738-2

Marital Status: Married and mother to Tom and Idan

Permanent Home Address: 5 Mosinson St. Tel Aviv 62965, Israel

Home Telephone Number: Tel: 972-3-5446086

Office Telephone Number: Tel: 972-3-5446086

Electronic Address: [email protected]

Fax Number: Tel: 972-3-5446086

2. Higher Education

A. Under graduate and Graduate Studies

Date of Degree Degree Name of Institution and Department Period of Study

September 1998 B.Sc Nutrition Sciences in the Agriculture Faculty,

Hebrew University

1995- 1998

August 2007 Ph.D

Direct

course

Epidemiology and Preventive Medicine,

Sackler School of Medicine, Tel Aviv

University

2001- 2007

B. Post-Doctoral Studies

Year of Completion Name of Institution, Department and Host Period of Study

2008 Tel-Aviv Sourasky

Medical Center, Department of Gastroenterology

and Hepatology.

Prof. Ran Oren

2008

2009 Pierre and Marie Curie University, Paris, France.

Prof. Vlad Ratziu

2009

2

3. Academic Ranks and Tenure in Institutes of Higher Education

Rank/Position Name of Institution and Department Dates

Lecturer School of Public Health, Faculty of Social Welfare and

Health Sciences, University of Haifa

2009-2013

Senior Lecturer School of Public Health, Faculty of Social Welfare and

Health Sciences, University of Haifa

2013-present

Note: * represent activities since last appointment.

4. Offices in University Academic Administration

* 2011-

present

Responsible for research committee at the School of Public Health,

Faculty of Social Welfare and Health Sciences, University of Haifa.

2013-

present

Head of nutrition and behavior stream (starting on March 2013) at

the School of Public Health, Faculty of Social Welfare and Health

Sciences, University of Haifa.

2013-

present

A member at the department of Nutrition, Law and Ethics, Center

for Health, Law and Ethics, University of Haifa.

* 2013-

present

Responsible for the PhD forum at the School of Public Health,


* 2014-

present

A member at the PhD committee of the school of public health


5. Scholarly Positions and Activities outside the University

a. Professional Experience

1999- present Dietitian and Researcher. Tel-Aviv Sourasky Medical

Center

1999- 2009 Dietitian and Group manager. Clalit Healthcare Services.

1999-2001 Manager of the nutrition field in "Mishan" Givataim

3

geriatric institute.

2006-2007 Manager of internet nutrition forum for Clalit Health

Services.

2009-2010 Researcher responsible for the construction of a long

term health promotion program for low socioeconomic

population. The Samuel Neaman Institute, the Technion.

2012- present A member of the editorial board of "Liver International".

2012- present A member at the National Committee for Nutrition,

Gastroenterology and Liver Disease, the Ministry of

Health.

2012-2013 A member at the Israel Science Foundation (ISF) Public

health committee.

2013-present A member of the editorial board of "World journal of

Gastroenterology".

*2014 A member at the scientific team writing position

statement with guidelines on nutrition for cardiovascular

disease prevention on behalf of the Israel heart society.

*2014 Guest Editor of a special topic "Non-Alcoholic

Steatohepatitis: Pathogenesis and Clinical

Management", BioMed Research International.

b. Membership in Professional Associations

2000- present The Israeli Nutrition Association – ATID.

2002- present The Israeli Association for the Study of the Liver.

2010- present The European Association for the Study of the Liver (EASL).

2012- present The American Association for the Study of the Liver (AASLD).

4

6. Participation in Scholarly Conferences

a. Active Participation- Abroad

Role Subject of Lecture/ Discussion /Comments /poster

Place of Conference

Name of Conference

Date No.

Poster The prevalence of primary nonalcoholic fatty liver disease in the Israeli population and the association with biochemical and anthropometric measures.

Lisbon European Association for the Study of the Liver

09/04 1.

Oral presentation

A double-blind randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic fatty liver disease.

Boston American Association for the Study of Liver Diseases

10/04 2.

Poster Does weight loss improve liver histopathology in nonalcoholic fatty liver disease?

Paris European Association for the Study of the Liver

04/05 3.

Poster 1) Increased prevalence of nonalcoholic fatty liver disease in patients with acute myocardial infarction independent of BMI.

San Francisco

American Association for the Study of Liver Diseases

11/05 4.

Poster 2) Is nonalcoholic fatty liver disease an independent predictor of the metabolic syndrome?

5.

Poster 3) Hyperinsulinemia is a predictor of elevated serum ALT levels even after adjustment to nonalcoholic fatty liver disease and liver histology.

6.

Poster Serum ALT is not a reliable screening tool for nonalcoholic fatty liver disease in the general population.

Vienna European Association for the Study of the Liver

04/06 7.

5


Place of Conference

Name of Conference

Date No.

Poster Long term nutritional intake and the risk for non-alcoholic fatty liver disease; A population based study.

Barcelona European Association for the Study of the Liver

04/07 8.

Poster Role of physical activity in non-alcoholic fatty liver disease (NAFLD): A population based study.


11/07 9.

Poster A comparison between the hepatorenal ultrasound index and steatotest for the non-invasive quantification of liver steatosis.

Milan European Association for the Study of the Liver

04/08 10.

Poster Can serum leptin and adiponectin predict liver injury in patients with NAFLD? A study in the general population.

Copenhagen European Association for the Study of the Liver

04/09 11.

Poster Discordance between three successive Fibroscan measurements mirrors the variability of liver fibrosis.

Copenhagen European Association for the Study of the Liver

04/09 12.

6


Place of Conference

Name of Conference

Date No.

Keynote speaker and a speaker in a panel discussion

Effect of diet, exercise and anti-obesity drugs on non-alcoholic fatty liver disease.

Bologna European Association for the Study of the Liver

09/09 13.

Poster 1) A comparison of fatty liver index with three non-invasive methods for the detection and quantification of liver steatosis: regular ultrasound, hepatorenal ultrasound index and steatotest.

Vienna European Association for the Study of the Liver

04/10 14.

Poster 2) The hepatorenal ultrasound index is correlated with obesity, ALT, insulin and adipocytokines.

15.

Invited speaker

Case study: lifestyle modification in a patient with fatty liver.

Torino European Association for the Study of the Liver Clinical School of Hepatology

05/10 16.

Poster 1) Comparison of FibroTest to other calculated scores for liver fibrosis as a screening for advanced NAFLD in the general population.

Nice European Association for the Study of the Liver

01/11 17.

Poster 2) Is there an association between coffee consumption and NAFLD or presumed NASH and fibrosis in a general adult population?

18.

Poster Incidence and regression rates of NAFLD in seven years follow up of a cohort from the general population.

Berlin European Association for the Study of the Liver

04/11 19.

Keynote speaker

Metabolic and clinical aspects of fructose, soft drinks, and obesity-related disorders.

Athens, Georgia

University of Georgia global health symposium

09/11 20.

7


Place of Conference

Name of Conference

Date No.

Keynote speaker and a judge in poster competition

Lifestyle and diet: What evidence for impact on NAFLD progression?

Stockholm United European Gastroenterology Week

10/11 21.

Oral presentation

1) The effect of resistance training on non-alcoholic fatty liver disease a randomized clinical trial.

Barcelona European Association for the Study of the Liver

04/12 22.

Poster 2) Depression is independently associated with elevated liver enzymes in employees undergoing health screening examinations.

23.

Poster 3) NAFLD independently predicts type-2 diabetes and pre-diabetes during 1 seven-year prospective follow-up.

24.

Poster 4) A phase-2, randomized, double blind, placebo-controlled trial of Aramchol for the treatment of non alcoholic fatty liver disease.

25.

Poster Elevated Alanine transaminase predicts new onset of depression in employees undergoing health screening examinations.


11/12 26.

Poster oral presentation

Non-high density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease in a 7 year prospective follow-up

Amsterdam European Association for the Study of the Liver

04/13 27.

Keynote speaker

Lifestyle as a treatment for non alcoholic fatty liver disease.

Barcelona 10th International Liver Therapy Meeting

09/13

28.

Chair a symposium and a speaker

Future prospective in the treatment of obesity

London European Association for the Study of the Liver

*04/14 29.

8


Place of Conference

Name of Conference

Date No.

Poster oral presentation

Coffee does not prevent development of NAFLD but may delay fibrosis progression: A prospective cohort study in the general population

London European Association for the Study of the Liver

*04/14 30.

Active Participation- In Israel

Oral presentation

Role of noninvasive tests in the classification of nonalcoholic fatty liver disease.

Eilat The Israeli Association for the Study of the Liver

12/02 1.

Oral presentation

Factors modulating serum alanine aminotransferase (ALT) in patients with nonalcoholic fatty liver disease.

Haifa The Israeli Gastroenterology Association

02/03 2.

Oral presentation

Double blind randomized placebo-control trial of Orlistat, for the treatment of primary nonalcoholic fatty liver disease.

Herzliya The Israeli Gastroenterology Association

06/04 3.

Oral presentation

Double blind randomized placebo-control trial of Orlistat, for the treatment of primary nonalcoholic fatty liver disease.

Tel-Aviv The Israeli Association for the Research and Treatment of Obesity

06/04 4.

Oral presentation

Is NAFLD an independent predictor of the metabolic syndrome?


02/05 5.

Oral presentation

Nonalcoholic fatty liver disease and hyperinsulinemia are major determinants of serum ferritin levels.


03/06 6.

9


Place of Conference

Name of Conference

Date No.

Oral presentation

Role of physical activity in non-alcoholic fatty liver disease: A population based study.

Tiberias The Israeli Gastroenterology Association

12/07 7.

Oral presentation

A comparison between the hepatorenal ultrasound index and steatotest for the non-invasive quantification of liver steatosis.


03/08 8.

Oral presentation

Discordance between three successive Fibroscan measurements mirrors the variability of liver fibrosis.

Kfar Blum The Israeli Association for the Study of the Liver

03/09 9.

Oral presentation

A comparison of fatty liver index with three non-invasive methods for the detection and quantification of liver steatosis.


03/10 10.

Oral presentation

1) The effect of resistance training on non-alcoholic fatty liver disease a randomized clinical trial.


03/12 11.

Oral presentation

2) NAFLD independently predicts pre-diabetes during 1 seven-year prospective follow-up.

12.

Poster The effect of resistance training on non-alcoholic fatty liver disease a randomized clinical trial.

Tel-Aviv Faculty of Medicine, Tel-Aviv University

05/12 13.

Oral presentation

Non-HDL cholesterol as an independent predictor for NAFLD.


06/13 14.

Poster Coffee does not prevent the development of NAFLD in a prospective cohort but may decrease fibrosis


06/14 15.

10

b. Organization of Conferences or Sessions

Subject of Conference/ Role at Conference/ Comments

Place of Conference

Name of Conference

Date

Updates in nutrition/ chairperson, organizer and head of committee assembling position statement on behalf of ATID.

Herzliya, Israel The Israeli dietitians Association – ATID professional conference

11/08 1.

Nutritional treatment for liver diseases/ chairperson and organizer.

Tel-Aviv, Israel Nutrition Medical Conference

01/10 2.

Olive oil and health, scientific session/ chairperson and organizer.

Jerusalem, Israel

International Olive oil conference TERRAOLIVO

05/11 3.

Updates in nutrition/ chairperson and a member on the steering committee.

Shfaim, Israel

The Israeli dietitians Association – ATID professional conference

09/12 4.

Childhood obesity, ethical and research aspects/ chairperson and a member on the steering committee.

Haifa, Israel

School of Public Health, University of Haifa

12/12 5.

Microbiota and gastrointestinal and liver diseases.


*01/14 6.

Gastroenterology forum. Ramat-Gan, Israel


*09/14

7. Invited Addresses

Presentation/Comments Name of Forum Place of Lecture Date

Physical activity and nutrition for the elderly.

Geriatric medical Conference

Tel-Aviv, Israel 09/00 1.

Biochemical aspects and pathogenesis of nonalcoholic fatty liver disease.

The Israeli Organization of Medical Laboratories

Tel-Aviv, Israel 01/03

2.

Nonalcoholic fatty liver disease- a new old disease.

Nutrition Medical Conference


11


Nonalcoholic fatty liver disease. The Israeli family physicians association conference

Eilat, Israel 04/03 4.

Nonalcoholic fatty liver disease in children.

A pediatric conference in the Tel Aviv Sourasky Medical Center

Tel-Aviv, Israel 07/03

5.

The epidemiology of primary nonalcoholic fatty liver disease in Israel.

The Israeli Association for the Study of the Liver

Herzliya, Israel 09/04 6.

The metabolic syndrome, MABAT from the liver.



The nutritional treatment of nonalcoholic fatty liver disease.

Nutrition Medical Conference of Clalit Health Services


Vitamins and minerals in human health.


Ramat-Gan, Israel 02/06 9.

Pediatric nonalcoholic fatty liver disease.


Raanana, Israel 08/07 10.

Nutritional management In liver diseases.

Conference by "Hets"–The Israeli association for patients with liver diseases


The association between viral hepatitis B & C and insulin resistance.

Nurses conference by "Schering-Plough"


What's between probiotics and non-alcoholic fatty liver disease.



The association between egg consumption and cardiovascular disease - Evidence Based Medicine.


Herzliya, Israel 11/08 14.

The association between soft drinks and fructose consumption and obesity, fatty liver and diabetes.


Raanana, Israel 05/09 15.

Effect of diet, exercise and anti-obesity drugs on non-alcoholic fatty liver disease.

The Israeli Association for the Study of the Liver

Ramat-Gan, Israel 09/09 16.

Update in diet and physical activity for the treatment of NAFLD.


01/10 17.

12


Nutrition in viral liver disease and cirrhosis.

Nutrition Medical Conference of Carmel Hospital

Haifa, Israel 02/10 18.

Effect of olive oil in the Liver.

International Olive oil conference TERRAOLIVO

Jerusalem, Israel 05/11 19.

The association between probiotics and liver diseases.


Shfaim Israel

09/12 20.

The nutritional treatment of liver diseases.


Wohl-center Israel

10/12 21.

Metabolic and clinical aspects of sugar and fructose.

Tnuva Research institute

Herzliya, Israel *10/13 22.

The nutritional treatment of liver diseases.

The Israeli family physicians association conference

Ramat-Gan, Israel *06/14 23.

The dual association between type-2 diabetes and NAFLD


Ramat-Gan, Israel *09/14 24.

8. Colloquium Talks

Presentation/Comments Name of Forum Place of Lecture

Date

Clinical and nutritional aspects of nonalcoholic fatty liver disease.

Dept. of Nursing, Tel Aviv University

Tel-Aviv, Israel

11/02 1.

Case studies in nonalcoholic fatty liver disease.

Maccabi Healthcare course for Family Physicians

Ramat-Gan, Israel

06/04 2.

Nutritional management in nonalcoholic fatty liver disease.

Nutrition trainee's course, National Training Center, Ministry of Health

Tel-Hashomer, Israel

05/06 3.

Nutritional treatment for cirrhosis. Nutrition seminar of Clalit Health Services

Tel-Aviv, Israel

10/08 4.

Nutrition in the pathogenesis and treatment of nonalcoholic fatty liver disease.

A conference for physicians from eastern Europe, Tel Aviv Sourasky medical center

Tel-Aviv, Israel

12/08 5.

Soft drinks consumption and obesity and fatty liver.

Nutrition conference, Clalit Health Services

Raanana, Israel

05/09 6.

13


Date


Gastroenterology course for medical students at the Tel-Aviv University (the 4 years program)

Tel-Aviv, Israel

03/10 7.


A conference for physicians from Kazakhstan at the Tel Aviv Sourasky medical center

Tel-Aviv, Israel

07/10 8.

Role of nutrition in liver And cardiovascular diseases.

Nutrition seminar of Maccabi Healthcare

Ramat-Hasharon, Israel

07/10 9.

Nutrition and obesity in view of public health and primary prevention.

Health promotion course for 6th year medical students at the Tel-Aviv University

Tel-Aviv, Israel

10/10 10.


Gastroenterology course for medical students at the Tel-Aviv University (the 4 years program)

Tel-Aviv, Israel

03/11 11.

Nutrition in the pathogenesis and treatment of pediatric nonalcoholic fatty liver disease.

Institute for Endocrinology and Diabetes, at Schneider Children’s Medical Center

Petah Tikva, Israel

02/13 12.

Nutritional treatment of liver disease and cirrhosis.

The Israeli Nutrition Association – ATID gastroenterology course

Rehovot, Israel

06/13 13.

Advances in the research of obesity.

The annual conference of the School of Public Health

Haifa, Israel 06/13 14.

Nonalcoholic fatty liver disease and diabetes mellitus.

Nutritional treatment of diabetes course

Tel-Aviv, Israel

07/13

15.

Nutritional epidemiology. Health promotion seminar of Maccabi Healthcare

Tel-Aviv, Israel

*02/14 16.



Tel-Aviv, Israel

*02/14

17.

Nutritional treatment of liver disease and cirrhosis.

The Israeli Nutrition Association – ATID gastroenterology course

Rehovot, Israel

*03/14 18.

Supportive nutritional treatment in viral hepatitis

MSD workers Tel-Aviv, Israel

*03/14 19.

Epidemiological research in nonalcoholic fatty liver disease.

The Weizmann Institute of Science- metabolic seminar

Rehovot, Israel

*06/14 20.

14


Date



Tel-Aviv, Israel

*07/14

21.

9. Research Grants

a. Grants Awarded

In all grants awarded the entire fund amount was assigned to me.

Publications Year Award NIS

Funded by Topic Co-Researchers

Role in Research

D#2, D#5 2002

40,000 Tnuva Research Fund.

Calcium intake and the metabolic syndrome

Prof. Ran Oren

Co-PI

D#2 2005 20,000 Research fund of the Institute for the Research of the Influence of Food on Human Health and Quality of Life.

The Prevalence of primary nonalcoholic fatty liver disease in the Israeli population and the association with biochemical and anthropometric measures

Prof. Ran Oren

PI

_ 2009 25,000 Chief Scientist Office, Ministry of Health, feasibility study.

The association between treatment with drugs inhibiting the renin-angiotensin (RAS) system and NAFLD in type-2 diabetic patients

Prof. Ran Oren Dr. Hanny Yeshua

Co-PI

_ 2010 10,000 Pfizer research grant.

Screening policy for cardiovascular disease in Israel: should Non-HDL cholesterol be routinely included in risk assessment?

Dr. Hanny Yeshua Samah Haiek

PI

_ 2011 10,000 Pfizer research grant.

Trends in serum 25(OH)D distribution in the Israeli population in the last decade

Prof. Tamar Shohat

PI

15

Publications Year Award NIS

Funded by Topic Co-Researchers

Role in Research

_ 2013 37,000 Pfizer research grant

Comparing Physician Cardiovascular Disease Risk Factor Management in Israel and the United States

Dr. Richard J Schuster, Dr. Hanny Yeshua, Dr. Colleen O’Brien Cherry

Co-PI

_ 2013 12,000 Pfizer research grant

Estimation of liver disease burden in Israel by postmortem material for the establishment of a screening policy in children and adults

Dr. Salman Zarka

PI

_ 2014 600,000 Fund on Food and Nutrition with Implications on Public Health. Chief Scientist Office, Ministry of Health

A cross sectional study on nutrients intake, diet pattern and the microbiota profile among bariatric surgery candidates

Dr. Oren Shibolet Dr. Eran Elinav

Co-PI

b. Submission of Research Proposals – Pending

Year Funded by Topic Co-Researchers Role in Research

2013 Weizmann Institute of Science – Tel Aviv Medical Center Collaborative Grant $100,000

A step towards personalized drug treatment-elucidating the role of gut pharmaco-microbiomics in drug induced liver injury

Dr. Oren Shibolet Dr. Eran Elinav

*Researcher

16

c. Submission of Research Proposals – Not Funded

Score Year Funded by Topic Co-Researchers Role in Research

- 2010 Pre-proposal for the Middle East Regional Cooperation Program (MERC). $ 598,000

Detection and treatment of non-alcoholic fatty liver disease as a means of controlling the epidemic of diabetes mellitus in the Israeli and Palestinian populations

Dr. Arafeh Nabil Dr. Raed Titi Prof. Manfred Green Prof. Ran Oren

PI

- 2010 Pre-proposal for the MINERVA Center. € 150,000 per year

Establishment of a center on biological, clinical and public health aspects of liver diseases and obesity

Prof. Manfred Green Prof. Heiner Wedemeyer Prof. Ran Oren

Co-PI

- 2010 Pfizer research grant. 10,000 NIS

Building evidence to public health policy aimed at reduction of soft drinks consumption

Hala Nseir Dr. Assy Nimer

PI

- 2010 Research fund of the Institute for the Research of the Influence of Food on Human Health and Quality of Life. 20,000 NIS

Fatty liver, adipocytokines and nutrition in the prediction of metabolic disorders in the general Israeli population

Prof. Ran Oren Roni Lotan

PI

- 2010 Dr. Sima Lior Fund. 140,000 NIS

The Role of resistance training in non alcoholic fatty liver disease, randomized clinical trial

Prof. Ran Oren Co-PI

- 2010 Chief Scientist Office, Ministry of Health. 317,680 NIS

The influence of soft drinks on serum levels of Advanced Glycation End Products and metabolic and inflammatory markers in patients with non-alcoholic fatty liver

Dr. Assy Nimer Co-PI

- 2010 Chief Scientist Office, Ministry of Health, feasibility study. 40,000 NIS

The Role of resistance training in non alcoholic fatty liver disease, randomized clinical trial

Prof. Ran Oren Co-PI

17


- 2010 Clalit Healthcare Services research fund. 130,000 NIS.

The prevalence of primary nonalcoholic fatty liver disease in low socio-economic Israeli population, and the association with obesity, nutritional intake and susceptibility to diabetes

Prof. Ran Oren and Dr. Hanny Yeshua

Co-PI

- 2011 The Israel National Institute for Health Policy and Health Services Research. 150,000 NIS

Trends in serum 25(OH)D distribution in the Israeli population in the last decade

Prof. Manfred Green

PI

- 2011 Israel Ministry of Defence grant

97,500 NIS

Non alcoholic fatty liver disease (NAFLD) as predictor of diabetes mellitus, cardiovascular disease and advanced liver disease in staff members of the Israeli army- long term prospective follow-up

Dr. Oren Shibolet PI

- 2011 Italy-Israel Cooperation Scientific grant € 40,000

Association among Advanced Glycation End Products, Cytokines and dietary habits in patients with non-alcoholic fatty liver disease

Prof. Fabio Galvano Co-PI

- 2011 Deutsche Forschungsgemeinschaft Trilateral Projects. € 1,000,000

Ethnic and clinical differences in Non-alcoholic fatty liver disease: A prospective study in three diverse populations

Dr. Oren Shibolet Prof. Ziad Abdeen Prof. Manfred Green Prof. Michael Manns Prof. Heiner Wedemeyer

Co-PI

- 2012 Chief Scientist Office, Ministry of Health 200,000 NIS

The association between dietary consumption of milk and dairy, with colorectal polyps and their neoplastic potential

Dr. Revital Kariv Naomi Fliss Prof. Zamir Halpern

*Co-PI

- 2012 Chief Scientist Office, Ministry of Health200,000 NIS

The association between dietary consumption, with colorectal polyps and their neoplastic potential

Dr. Revital Kariv Naomi Fliss Prof. Zamir Halpern

Co-PI

18


- 2013 The Israel Science Foundation (ISF) $311,000

Discriminatory metabolic, inflammatory and lifestyle parameters between the "metabolically healthy" and the "metabolically unhealthy" obese individuals

_ PI

10. Scholarships, Awards and Prizes

2007 Young investigator award for the best poster, The European Association

for the Study of the Liver.

11. Teaching

a. Courses Taught in Recent Years

Number of Students

Degree B.A./M.A./M.Sc/Ph.D.

Type of Course Lecture/Seminar/Workshop

Name of Course Year

80 B.A Workshop Nutrition in liver diseases

2006-2011

50 None (Ridman" natural medicine college)

Lectures Medical nutrition 2007-2009

8 M.A./M.Sc/Ph.D. Lectures Meta analysis 2008- present

20 M.A./M.Sc/Ph.D. Lectures Making sense of data 2009- present

23 M.A./M.Sc/Ph.D. Lectures Nutritional Epidemiology

2009- present

30 M.A./M.Sc/Ph.D. Lectures Construction of a research proposal

2009- present

10 M.A./M.Sc/Ph.D. Lectures Epidemiology of cardiovascular disease

2010- present

8 M.A./M.Sc/Ph.D. Lectures Applied research 2010- present

25 Pre-med students Lectures Epidemiology 2013- present

12 M.Sc/Ph.D. Lectures Advanced clinical nutrition

2014

19

b. Supervision of Graduate Students

Student's Achievements

Date of Completion /in Progress

Degree Title of Thesis Name of Student

See D#14, D#20, D#22

Completion

2012 (score 89)

M.Sc

Incidence of nonalcoholic fatty liver disease and the metabolic syndrome components, a follow up study

Lotan Roni Co-supervisor

Prof. Oren Ran

- Completion

2011 (score 90)

MD research adviser

Hepato-renal index (HRI) and anthropometric and biochemical measures among patients of the fatty liver clinic

Isaak Winocur Michal

See K#1 Completion

2013 (score 93)

M.Sc

Physical activity as a treatment for nonalcoholic fatty liver disease

Buch Assaf Co-supervisor Dr. Shibolet Oren

- in Progress M.Sc

Knowledge attitudes and practice of nonalcoholic fatty liver disease patients with regard to lifestyle modification as compared to diabetic patients

Dror-Lavi Gali

See M#1 Completion

2013 (score 88)

M.Sc

Factors associated with adherence to weight reduction and physical activity program in obese children

Ben Abu Maya

See M#2 Completion

2013 (score 94)

M.Sc

Exposure to passive smoking among Arab women with acute MI as compared to controls

Awawdi Khaled†

See M#3 Completion

2013 (score 92)

M.Sc

The association between viral hepatitis and the metabolic syndrome

Yair-Sabag Shira

- in Progress M.Sc

Knowledge, attitudes and practice towards soft drinks consumption among adult Arab population

Jamal Asuan

- in Progress M.Sc

Non-HDL cholesterol and cardiovascular mortality

Abed Petra

See M#4 Completion 2013 (score 93)

M.Sc

Physical activity at work and at leisure time and all cause and cardiovascular mortality

Harari Gil Co-supervisor Prof. Green Manfred

- in Progress M.Sc

Nutritional pattern and nonalcoholic fatty liver disease

Solomon Esti

- in Progress M.Sc

The association between non alcoholic fatty liver diseases (NAFLD)

Schlesinger Dalit

20

Student's Achievements

Date of Completion /in Progress

Degree Title of Thesis Name of Student

and quality of life (QOL) parameters and utilization of health service in Israeli Jewish population

- in Progress M.Sc

Disordered eating (night and binge eating) among morbid obese patients and the association with hepatic fibrosis

Shoham Dafna

- in Progress M.Sc

The association between state and trait anxieties, dietary patterns and non alcoholic fatty liver disease

Goldshmidt Moyal Reut

- in Progress M.Sc

Anxiety from eating and eating patterns among inflammatory bowel disease patients

Moria Damari

- in Progress Ph.D

The association between adenomas and nonalcoholic fatty liver disease

Phlis Naumi Co-supervisor Dr. Kariv Revital

- in Progress Ph.D

Probiotics vs. antibiotic as a treatment for fatty liver patients, randomized double blind clinical trial

Sherf Shiri Co-supervisor Dr. Shibolet Oren

- in Progress Ph.D

Development of a risk prediction model for cardiovascular mortality in the CORDIS cohort

Harari Gil Co-supervisor Prof. Green Manfred

PUBLICATIONS

Note: In accordance with accepted procedure for medical and science authorship

order, first or last placement of name indicates that author played the major role in

the reported study, unless mentioned otherwise.

A. Ph.D. Dissertation

Title: The prevalence of primary nonalcoholic fatty liver disease (NAFLD)

in Israeli population, and the association with biochemical,

anthropometric and nutritional measures.

Date: May 2007

No of pages: 168

21

Language: English

University: Sackler School of Medicine, Tel Aviv University.

Names of supervisors (Ph.D):

Prof Ran Oren, M.D. Sackler School of Medicine, Tel Aviv University.

Prof Zamir Halpern, M.D. Sackler School of Medicine, Tel

Aviv University.

Dorit Nizan Kaluski, M.D., MPH, R.D. Sackler School of Medicine, Tel Aviv

University.

See publication list: D#2, 4, 5, 8.

B. Scientific Books (Refereed)

None

C. Monographs

None

22

D. Articles in Refereed Journals

Published

* Denotes activities & publications since last appointment # My student + Corresponding author

1. +Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,

Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2006). A double-blind randomized

placebo-controlled trial of Orlistat for the treatment of nonalcoholic fatty liver

disease. Clinical Gastroenterology and Hepatology. (4) 639-44.

IF 5.63

2. +Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2006).

Prevalence of primary NAFLD in a population-based study and its association with

biochemical and anthropometric measures. Liver International. (26) 856-63.

IF 3.824

3. Kariv, R., Leshno, M., Beth-Or, A., Strul, H., Blendis, L., Kokia, E., Noff, D., Zelber-

Sagi, S., Sheinberg, B. Oren, R., Halpern, Z. (2006). Re-evaluation of serum alanine

aminotransferase upper normal limit and its modulating factors in a large-scale

population study. Liver International. (26) 445–50.

IF 3.824

23

4. +Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2007).

NAFLD and serum insulin are major determinants of serum ferritin levels.

Journal of Hepatology. (46) 700-7.

IF 9.264

Related editorial:

Trombini, P., Piperno, A. Ferritin, metabolic syndrome and NAFLD: Elective

attractions and dangerous liaisons. (2007) Journal of Hepatology. (46) 549-52.

5. +Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, L., Halpern,

Z., Oren, R. (2007). The association between NAFLD and long term nutritional

intake, a population based study. Journal of Hepatology. (47) 711-7.

IF 9.264

6. Lurie, Y., Landau, DA., Kanevsky, A., Pel, S., Zelber-Sagi, S., Oren, R. (2007). Medex

test, a novel modality for liver disease diagnosis: a pilot study. Journal of Clinical

Gastroenterology. (41) 700-5.

IF 3.159

7. Lurie, Y., Landau, DA., Blendis, L., Baruch, Y., Veitsman, E., Ackermann, Z., Zelber-

Sagi, S., Halpern, Z., Oren, R. (2007). Acute hepatitis C in Israel: a predominantly

iatrogenic disease? Journal of Gastroenterology and Hepatology. (22) 158-64.

IF 2.865

http://www.ncbi.nlm.nih.gov/pubmed/17667055




24

8. +Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner,

I., Blendis, L., Halpern, Z., Oren, R. (2008). Role of leisure-time physical activity in

non-alcoholic fatty liver disease (NAFLD): A population based study. Hepatology.

(48) 1791-8.

IF 11.665

9. +Webb, M., Yeshua, H., Zelber-Sagi, S., Santo, M., Brazowski, E., Halpern, Z.,

Oren, R. (2009). The Diagnostic Value of a Computerized Hepatorenal Index for

Ultrasonographic Quantification of Liver Steatosis. American Journal of

Roentgenology. (192) 909-14.

IF 2.47

10. *Ratziu, V., Zelber-Sagi, S. (2009). Pharmacologic therapy of non-alcoholic

steatohepatitis. Review. Clinics in Liver Disease. (13) 667-88.

IF 3.180

11. *+Zelber-Sagi, S., Ratziu, V., Oren, R. (2011). Nutrition and physical activity in

NAFLD – an overview of the epidemiological evidence. Review. World Journal of


IF 2.471

Related "Topic highlight":

Nimer, A. (2011). Nutritional recommendations for patients with non-alcoholic

fatty liver disease. World Journal of Gastroenterology. (17) 3375–6.

25

12. *+Zelber-Sagi, S., Yeshua, H., Shlomai, A., Blendis, L., Leshno, M., Levit, S., Halpern,

Z., Oren, R. (2011). Sampling variability of transient elastography according to

probe location. European Journal of Gastroenterology & Hepatology. (23) 507-14.

IF 1.757

13. *Maharshak, N., Halfon, P., Deutsch, V., Peretz, H., Berliner, S., Fishman, S., Zelber-

Sagi, S., Rozovski, U., Leshno, M., Oren, R. (2011). Increased fibrosis progression

rates in hepatitis C patients who carry the PTG20210A mutation. World Journal of


IF 2.471

14. *+Zelber-Sagi, S., #Lotan, R., Shlomai, A., Webb, M., Harrari, G., Buch, A., Nitzan-

Kaluski, D., Halpern, Z., Oren, R. (2012). Predictors for incidence and remission of

NAFLD in the general population during a seven-year prospective follow-up. Journal

of Hepatology. (56) 1145-51.

(The first and the second authors contributed equally to the paper).

IF 9.264

15. *+Zelber-Sagi, S., Ratziu, V., Zvibel, I., Goldiner, I., Blendis, L., Morali, G., Halpern,

Z., Oren, R (2012). The association between adipocytokines and biomarkers for

nonalcoholic fatty liver disease-induced liver injury: a study in the general

population. European Journal of Gastroenterology & Hepatology. (24) 262-9.

IF 1.757

26

16. *Salamone, F., Volti, GL., Titta, L., Barbagallo, I., Puzzo, L., Zelber-Sagi, S., Pelicci,

PG., Giorgio, M., Galvano, F. (2012). Moro orange juice prevents fatty liver in mice.

World Journal of Gastroenterology. (18) 3862-8.

IF 2.471

17. *Shlomai, A., Halfon, P., Goldiner, I., Zelber-Sagi, S., Halpern, Z., Oren, R., Bruck,

R. (2013). Serum Bile acid levels as a predictor for the severity of liver fibrosis in

patients with chronic hepatitis C. Journal of Viral Hepatitis. (20) 95-102.

IF 3.502

18. *+Zelber-Sagi, S., Webb, M., Assy, N., Blendis, L., Yeshua, H., Leshno, M., Ratziu,

V., Halpern, Z., Oren, R., Santo, E. (2013). Comparison of fatty liver-index with

non-invasive methods for steatosis detection and quantification. World Journal

of Gastroenterology. (19) 57-64.

IF 2.471

19. *+Zelber-Sagi, S., Toker, S., Armon, G., Melamed, S., Berliner, S., Shapira, I.,

Halpern, Z., Santo, E., Shibolet O. (2013). Elevated alanine transaminase

independently predicts new onset of depression in employees undergoing health

screening examinations. Psychological Medicine. (22) 1-11.

(The first and the second authors contributed equally to the paper).

IF 6.159

27

20. *+Zelber-Sagi, S., #Lotan, R., Shibolet, O., Webb, M., Buch, A., Nitzan-Kaluski, D.,

Halpern, Z., Santo, E., Oren, R. (2013). NAFLD independently predicts type-2

diabetes and pre-diabetes during a seven-year prospective follow-up. Liver

international. (33) 1406-12.

IF 3.824

21. *Safadi, R., Konikoff, F.M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T.,

Oren R; FLORA group. (2014). The fatty acid-bile acid conjugate Aramchol reduces

liver fat content in patients with nonalcoholic fatty liver disease. Clinical

Gastroenterology and Hepatology, 12(12) 2085-91.

22. *+Zelber-Sagi S., Buch A., Yeshua H., Vaisman N., Webb M., Harari G., Kis O., Fliss-

Isakov N., Izkhakov E., Halpern Z., Santo E., Oren R., Shibolet O. (2014). Effect of

resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

World Journal of Gastroenterology. 20(15) 4382-92.

23. *+Zelber-Sagi, S., Salamone, F., Yeshua, H., #Lotan, R., Webb, M., Halpern, Z.,

Santo, E., Oren, R., Shibolet, O. (2014). Non-high density lipoprotein cholesterol

independently predicts new onset of non-alcoholic fatty liver disease. Liver

international. 34(6) e128-35.

IF 3.824

28

Accepted for Publication

1. *+Endevelt, R., Ben-Assuli, O., Klain, E., Zelber Sagi, S. The role of the dietitian

follow-up in the success of bariatric surgery. Surgery for Obesity and Related

Diseases. Pages: 20.

IF 3.929

2. Khatib, M., Zvibel, I., Zelber-Sagi, S., Varol, C., Lahat, G., Abu-Abeid, S., Klausner, J.

M., Halpern, Z., & Fishman, S. (2014). Discriminatory metabolic and inflammatory

parameters in serum and omental adipose tissue of obese patients with different

insulin sensitivity. Journal of Clinical & Translational Endocrinology.

3. Zelber-Sagi, S., Salomone, F., Webb, M., Lotan, R., Yeshua, H., Halpern, Z., Santo,

E., Oren, R., Shibolet, O. (2014). Coffee consumption and non-alcoholic fatty liver

onset: a prospective study in the general population. Translational Research.

E. Articles or Chapters in Scientific Books

(which are not Conference Proceedings)

Accepted for Publication

1. *Zelber-Sagi, S. Diet and Lifestyle changes as treatment for NAFLD. In: Liver

metabolism and fatty liver disease. Florida: Taylor & Francis Group 2013.

Pages: 12.

29

2. *Zelber-Sagi, S., Yeshua, C., Shibolet, O., & Oren R. (2014). The fatty liver:

association with type 2 Diabetes and methods of treatment. In: A. Choen., O.

Mosenzone., & I. Raz (Eds.), The Guide for the treatment of diabetes (pp. 185-

196). Medical Group, The National Council of Diabetes and The Ministry of

Health: Tel – Aviv.

F. Articles in Conference Proceedings

Published

1. *Zelber Sagi S. Diet and Lifestyle changes as treatment for NAFLD. In: The 10th

Liver Therapy meeting. Barcelona: Elsevier Doyma 2013. 71-76.

G. Entries in Encyclopedias

None

H. Other Scientific Publications

Published

Abstracts

1. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,

Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2004). A double-blind randomized

placebo-controlled trial of Orlistat for the treatment of nonalcoholic fatty liver

disease. Hepatology. (40) 1069.

30

2. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,

Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2005). Does weight loss improve

liver histopathology in patients with NAFLD? Journal of Hepatology. Sup. (42)

705.

3. Kessler, A., Levy, Y., Roth, A., Zelber-Sagi, S., Leshno, M., Blendis, L., Halpern, Z.,

Oren, R. (2005).

Increased prevalence of NAFLD in patients with acute myocardial infarction

independent of BMI. Hepatology (42) 1084.

4. Zelber-Sagi, S., Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2005).

Is NAFLD an independent predictor of the metabolic syndrome?

Hepatology (42) 1069.


Hyperinsulinemia is an independent predictor of elevated serum ALT levels even

after adjustment to NAFLD and liver histology. Hepatology (42) 1081.


Serum ALT is not a reliable screening tool for NAFLD in the general population.

Journal of Hepatology. Sup. 2(44) 727.

31

7. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M., Halpern,

Z., Oren, R. (2007). The association between NAFLD and long term nutritional

intake, a population based study. Journal of Hepatology. Sup. 1(46) 291.

8. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M., Halpern,

Z., Oren, R. (2007). Role of physical activity in non-alcoholic fatty liver disease

(NAFLD): A population based study. Hepatology (46) 1150.

9. Zelber-Sagi, S., Webb, M., Ratziu, V., Poynard, T., Halpern, Z., Oren, R. (2008). A

comparison between the hepatorenal ultrasound index and steatotest for the

non-invasive quantification of liver steatosis. Journal of Hepatology. Sup. 2(48)

368.

10. Zelber-Sagi, S., Yeshua, H., Halpern, Z., Oren, R. (2009).

Discordance between three successive Fibroscan measurements mirrors the

variability of liver fibrosis. Journal of Hepatology. Sup. 1(50) 375.

11. Zelber-Sagi, S., Ratziu, V., Zvibel, I., Goldiner, I., Nitzan-Kaluski , D., Blendis, L.,

Gilles, M., Halpern, Z., Oren, R. (2009).

Can serum leptin and adiponectin predict liver injury in patients with NAFLD? A

study in the general population. Journal of Hepatology. Sup. 1(50) 375.

12. Zelber-Sagi, S., Webb, M., Leshno, M., Blendis, L., Yeshua, H., Ratziu, V., Halpern,

Z., Oren, R. (2010). A comparison of fatty liver index with three non-invasive

methods for the detection and Quantification of liver steatosis: Regular

32

ultrasound, hepatorenal ultrasound index and steatotest. Journal of Hepatology.

Sup. 1(52) 158.

13. Zelber-Sagi, S., Webb, M., Leshno, M., Blendis, L., Isaak Winocur, M., Yeshua, H.,

Halpern, Z., Oren, R. (2010). The hepatorenal ultrasound index is correlated with

obesity, ALT, insulin and adipocytokines. Journal of Hepatology. Sup. 1(52) 158.

14. Zelber-Sagi, S., Lotan, R., Webb, M., Halpern, Z., Oren, R. (2011). Incidence and

regression rates of NAFLD in seven years follow up of a cohort from the general

population. Journal of Hepatology. Sup. 1(54) 351.

15. Zelber-Sagi, S., Lotan, R., Shibolet, O., Webb, M, Buch, A., Nitzan-Kaluski, D.,

Halpern Z., Santo, E., Oren R. (2012). NAFLD independently predicts type-2

diabetes and pre-diabetes during a seven-year prospective follow-up. Journal of

Hepatology. Sup. 2(56) 526.

16. Zelber-Sagi, S., Toker, S., Shirom, A., Melamed, S., Berliner, S., Shapira, I.,

Halpern, Z., Santo, E., Shibolet O. (2012). Elevated Alanine transaminase


screening examinations. Journal of Hepatology. Sup. 2(56) 526.

17. Zelber-Sagi, S., Buch A., Yeshua H., Vaisman N., Harari, G., kiss O., Webb, M., Fliss,

N., Halpern, Z., Santo, E., Oren, R., Shibolet O. (2012). The effect of resistance

training on NAFLD a randomized clinical trial. Journal of Hepatology. Sup. 2(56)

33

526-7.

18. Zelber-Sagi, S., Toker, S., Shirom, A., Melamed, S., Berliner, S., Shapira, I.,

Halpern, Z., Santo, E., Shibolet O. (2012). Elevated alanine transaminase


screening examinations. Hepatology. Sup. 1(56) 1489.

(The first and the second authors contributed equally to the paper)

19. *+Zelber-Sagi, S., Buch, A., Yeshua, H., Vaisman, N., Harari, G., kiss, O., Webb, M.,

Fliss, N., Halpern, Z., Santo, E., Oren, R., Shibolet, O. (2012). The effect of

resistance training on NAFLD a randomized clinical trial. American journal of

Gastroenterology. Pages: 25. IF 7.282

(The first and the second authors contributed equally to the paper)

I. Other Publications

1. Zelber-Sagi, S., Oren, R. Non alcoholic fatty liver the hepatic manifestation of

the metabolic syndrome. Israeli journal of medicine. 8:25-30, 2007.

2. Zelber-Sagi, S., Oren, R. Non alcoholic fatty liver disease. In: Liver diseases.

Israel: Prolog publishing 2006.

3. Zelber-Sagi, S., Yeshua H., Oren, R. Fatty liver and diabetes. In: The guide for

the treatment of diabetes. Israel: The National Diabetes Committee, Ministry

of Health 2012.

34

4. *Zelber-Sagi, S., Yeshua H., Oren, R. Fatty liver and diabetes. In: The guide

for the treatment of diabetes. Israel: The National Diabetes Committee,

Ministry of Health 2014.

J. Other Works Connected with my Scholarly Field

None

K. Submitted Publications

L. Summary of my Activities and Future Plans

Field of Interest and Scientific Work

My research and publications address a wide spectrum of issues regarding non-alcoholic

fatty liver disease (NAFLD) including its prevalence in the general population, screening

methods, independent risk factors and the dual association with the metabolic

syndrome, biochemical characteristics and the association with nutrition and physical

activity. I also address different issues in nutritional and behavioral epidemiology as soft

drinks and health consequences, obesity and physical activity and mortality, vitamin D

and health, passive smoking and cardiovascular disease and the place of dietary

counseling after bariatric surgery.

1. Demonstrating that NAFLD is a prevalent disease in adult Israeli population with

insulin resistance, abdominal obesity and hypertriglyceridemia as independent

risk factors. These results emphasize the crucial role of central adiposity and the

mandatory use of fat distribution indices in metabolic disorders. Published.

35

2. Testing issues dealing with ALT, the most specific liver enzyme, including its

value as a screening tool for NAFLD. ALT was not an effective marker for NAFLD

at the population level. Published.

3. Since serum ferritin was suggested as one the components of the metabolic

syndrome and is closely associated with NAFLD, we further elaborated this

association by assembling, for the first time, all three variables into the equation.

According to our results, NAFLD may be considered as a possible mediator

between insulin resistance/ metabolic syndrome and serum ferritin levels.

Published.

4. Publishing one of the first epidemiological studies dealing with the

association of NAFLD with long term nutritional intake. Intake of soft drinks

and protein from all kinds of meat was found to be associated with increased

risk for NAFLD and intake of protein from fish rich in omega-3 tended to be

associated with a reduced risk for NAFLD. Published.

5. Publishing a paper demonstrating that higher leisure-time physical activity is

inversely associated with NAFLD. This association is independent of HOMA,

nutritional intake, adiponectin and resistin and for resistance physical activity

also of BMI. Published.

6. Quantification of liver steatosis is clinically relevant in various liver diseases,

but cannot be done by conventional ultrasound, which only provides a

qualitative assessment with significant observer variability. The aim of our

study was to test whether US can serve as an objective tool for the

quantification of hepatic steatosis by comparing computerized liver

echogenicity to that of the right kidney - hepatorenal ultrasound index (HRI).

36

We showed that HRI is a sensitive, reproducible, operator independent non-

invasive method for steatosis quantification. Published.

7. The incidence of nonalcoholic fatty liver disease (NAFLD) and the metabolic

syndrome components. The aim of our study is to describe the incidence of

NAFLD and the metabolic syndrome components, based on a follow up of a

general Israeli population previously screened for NAFLD. Published.

8. Adipocytokines and FibroMax (a set of biochemical markers for liver steatosis,

inflammation and fibrosis). The aim of this study is to evaluate whether liver

injury in NAFLD can be predicted by serum leptin and adiponectin. Leptin and

adiponectin have been implicated in the development of hepatic steatosis,

inflammation and fibrosis in NAFLD. We found that Adiponectin and leptin are

among the variables most strongly associated with steatosis and NASH but not

with fibrosis. Published.

9. Discordance between three successive Fibroscan measurements mirrors the

sampling variability of liver fibrosis. Transient Elastography (Fibroscan), a

noninvasive technique, can assess liver fibrosis by measuring liver stiffness from

various liver sites and thus helpful in estimating fibrosis variability. Almost one

third of the patients had some level of discordance between the three successive

Fibroscan measurements. Adopting the maximal or the minimal score may

change dramatically the diagnosis. Published.

10. A comparison of fatty liver index with three non-invasive methods for the

detection and quantification of liver steatosis: Regular ultrasound, hepatorenal

ultrasound index and steatotest. The paper deals with the comparison of

different screening tools for fatty liver in the general population. Published

(ahead of print).

37

Current Scientific Projects

1. A collaboration with the University of Georgia, Center for Global Health and with

Clalit Healthcare Services, in a survey comparing physician cardiovascular

disease risk factor management in Israel and in the United States.

2. Publishing the results of a randomized clinical trial about physical activity as a

treatment for nonalcoholic fatty liver (NAFLD). The effect of different physical

activity regimens were tested in NAFLD patients with regard to liver enzymes,

metabolic status, body composition and steatosis.

3. The initiation of a controlled clinical trial testing the influence of soft drinks on

serum levels of Advanced Glycation End Products (AGEs) and metabolic and

inflammatory parameters in patients with non-alcoholic fatty liver disease.

Several patients have been recruited.

4. A case-control study testing the association between adenomas and

nonalcoholic fatty liver disease. Data collection is preformed prospectively since

June 2010.

5. Data analysis from the CORDIS (cohort of Israeli employees) data-base with

regard to: non-HDL cholesterol and cardiovascular mortality, risk factors for

hepatocellular carcinoma, obesity and mortality, physical activity and

mortality.

6. Data collection and analysis about vitamin D and metabolic parameters in the

Israeli population, in collaboration with Maccabi Healthcare Services. We focus

38

on the association with NAFLD and pre-diabetes and the effect of

supplementation.

7. Re-evaluation of the normal range of vitamin D with historical cohort of blood

donors with cooperation of the ICDC. Initiation, writing grants and establishing a

research team.

8. Analyzing the Macabi health services date base on bariatric surgeries and

dietary treatment.

9. Collaborating with investigators from the Weizmann Institute of Science on the

association between dietary composition and the human microbiota.

10. The initiation of a randomized controlled clinical trial on the effect of antibiotic

and probiotic treatment in fatty liver disease patients.

11. The initiation of a survey on knowledge, attitudes and practice towards soft

drinks consumption among adult Arab population.

M. Works in Preparation

1. Factors associated with adherence to weight reduction and physical

activity program in obese children.

2. Exposure to passive smoking among Arab women with acute MI as

compared to controls.

3. The association between viral hepatitis and the metabolic syndrome.

4. Physical activity at work and at leisure time and all cause and cardiovascular

mortality.

5. Serum uric acid and elevated liver enzymes in the general population.

http://www.weizmann.ac.il/pages/

Name: Dr. Shira Zelber-Sagi Date: December...

Documents

Transcript of Name: Dr. Shira Zelber-Sagi Date: December...